Edesa Biotech is trading 5.19% lower at $2.56, but the reason for the October 30 decline remains uncertain. - No company announcement dated October 30 was found confirming the decline’s cause. - An October 29 report said the EB05 COVID-19 trial record had been updated to “terminated”; available coverage says this may weigh on shares but does not establish it as the cause. - Shares reversed after closing October 29 at $2.70, up 5.47%; no trading-volume confirmation was available.